JWH-193 explained

JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB₁ receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200,^[1] though with closer to twice the potency of JWH-200 in activity tests.

In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 are Schedule I Controlled Substances.

Related compounds

A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.^{[2] [3]}

See also

• JWH-122
• JWH-198

Notes and References

1. Huffman JW, Padgett LW . Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes . Current Medicinal Chemistry . 12 . 12 . 1395–411 . 2005 . 15974991 . 10.2174/0929867054020864 .
2. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM . 6 . Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics . Journal of Medicinal Chemistry . 38 . 16 . 3094–105 . August 1995 . 7636873 . 10.1021/jm00016a013 .
3. Shim JY, Collantes ER, Welsh WJ, Subramaniam B, Howlett AC, Eissenstat MA, Ward SJ . Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis . Journal of Medicinal Chemistry . 41 . 23 . 4521–32 . November 1998 . 9804691 . 10.1021/jm980305c .